Abstract
We isolate and culture carcinoma-associated fibroblasts (CAFs) from primary tumour (CAFpt), CAFs from corresponding synchronous liver metastasis (CAFlm) as well as normal colonic fibroblasts (NCF) from the same patient. From these cultures, conditioned media (CM) was obtained. Culture of a wide panel of colorectal and pancreatic cell lines in CM from CAFlm resulted in overexpression of mRNA PRL-3 and higher overexpression in CAFs than in non-activated fibroblasts. Moreover PRL-3 mRNA expression correlates with expression of α-SMA and deposition of collagen fibrils in the stroma. We demonstrate that products secreted by CAFs trigger PRL-3 overexpression in cancer cells. Identification of these factors may contribute to new stroma-targeted therapies for desmoplastic tumours.
Highlights
In many epithelial tumours inclouding colorectal, the relevance of PRL-3 phosphatase to the tumorigenic process of distant dissemination is well documented [1,2,3,4,5]
PRL-3 is overexpressed in different colorectal and pancreatic cell lines when cultured in conditioned media derived from carcinoma-associated fibroblasts from liver metastasis We cultured a wide panel of colorectal and pancreatic cell lines, derived from primary tumours and secondary sites
Same trend is observed between carcinomaassociated fibroblast from primary tumour (CAFpt) and carcinoma-associated fibroblasts derived from a liver metastasis (CAFlm) (P = 0.514)
Summary
In many epithelial tumours inclouding colorectal, the relevance of PRL-3 phosphatase to the tumorigenic process of distant dissemination is well documented [1,2,3,4,5]. B: normalised PRL-3 mRNA expression of DLD-1 cells cultured in conditioned media (CM) derived from fibroblasts and carcinoma-associated fibroblasts. (page number not for citation purposes) http://www.molecular-cancer.com/content/8/1/46 for 24 hours in their standard culture medium (DMEMF12 + 10%FBS) or in conditioned medium obtained from CAFs derived from a CRC liver metastasis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
